ADVERTISEMENT
Not Novel, but Effective! Sclerotherapy for Aneurysmal Bone Cyst
Marisabel Bolsegui discusses her CIO2023 abstract, "CIO 2023-14 Not Novel, but Effective! Sclerotherapy for Aneurysmal Bone Cyst."
Marisabel Bolsegui discusses her CIO2023 abstract, "CIO 2023-14 Not Novel, but Effective! Sclerotherapy for Aneurysmal Bone Cyst."
Summary
Marisabel Bolsegui discusses her CIO2023 abstract, "CIO 2023-14 Not Novel, but Effective! Sclerotherapy for Aneurysmal Bone Cyst."
Transcript
I'm Marissa Bolsegui. I'm an IR research fellow at Johns Hopkins, and I'm presenting a case about skull therapy for an arrhythmias bond cyst, ABC for short. These Canal lesions are osteolytic lesions that even though they are benign, they can cause very bothersome symptoms, including discomfort, pain, and loss of functionality.
So, this is a case of a 16-year-old boy that presented to the ER complaining of refractory pain for 6 months. After evaluation and imaging studies, he was diagnosed with an aneurysmal bone cyst. So, some surgical alternatives can be challenging because of anatomical constraints and lesions characteristic itself, and the course of action was to perform a sclerotherapy.
Through CT fluoroscopy two 18 and 19-gauge needles were inserted, obtaining fluid from the lesion, and contrast was given to confirm needle positioning. The chemical ablation was performed using 200 milligrams of doxycycline, human serum, I will make a 25% of concentration and contrast. Post procedure, of course, was uneventful, and the patient went home the same day. Follow-up was performed at 1, 3, and 6 months, and the findings on imaging were normal bone repolarization and normal healing changes. And at 12 months, at the 1-year follow-up, the patient was free of pain with increased functionality and improved quality of life. So that's why, even though it's not novel, sclerotherapy is a safe and effective treatment for aneurysmal bone.